96 related articles for article (PubMed ID: 955740)
21. Beta 2-microglobulin and HLA-DR expression in relation to the presence of Epstein-Barr virus in nasopharyngeal carcinomas.
Kouvidou C; Rontogianni D; Tzardi M; Datseris G; Panayiotides I; Darivianaki K; Karidi E; Delides G; Kanavaros P
Pathobiology; 1995; 63(6):320-7. PubMed ID: 8738471
[TBL] [Abstract][Full Text] [Related]
22. [Measurement of serum neopterin levels in patients with nasopharyngeal carcinoma and its significance].
Wang L; Jin S; Wei Q; Xiang J
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 May; 15(5):204-5. PubMed ID: 12541762
[TBL] [Abstract][Full Text] [Related]
23. Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance.
Laytragoon-Lewin N; Porwit-MacDonald A; Mellstedt H; Lewin F
Anticancer Res; 2000; 20(2B):1093-100. PubMed ID: 10810402
[TBL] [Abstract][Full Text] [Related]
24. Increased production of tumor necrosis factor-alpha and release of soluble CD4 and CD8 molecules, but decreased responsiveness to phytohemagglutinin in patients with nasopharyngeal carcinoma.
Kuo WR; Yu HS; Chang KL; Juan KH; Jan YS; Yu CL
J Formos Med Assoc; 1994 Jul; 93(7):569-75. PubMed ID: 7866054
[TBL] [Abstract][Full Text] [Related]
25. Impaired long-term T cell immunity to Epstein-Barr virus in patients with nasopharyngeal carcinoma.
Tamura S; Yamazaki A; Kunimoto M; Takemura K; Tabata T; Hinuma Y; Yoshie O
Jpn J Cancer Res; 1992 May; 83(5):445-9. PubMed ID: 1319984
[TBL] [Abstract][Full Text] [Related]
26. Lymphocyte subpopulations and mitogenic responses in nasopharyngeal carcinoma, prior to and after radiotherapy.
Lamelin JP; Ellouz R; De Thé G; Revillard JP
Int J Cancer; 1977 Nov; 20(5):723-8. PubMed ID: 200572
[TBL] [Abstract][Full Text] [Related]
27. [Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy and ginseng polysaccharide injection].
Xie FY; Zeng ZF; Huang HY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 May; 21(5):332-4. PubMed ID: 12577414
[TBL] [Abstract][Full Text] [Related]
28. [The influence of IL-2 on the immunologic function of the NPC patients treated with radiotherapy and chemotherapy].
Si Y; Wang P; Jiao W; Zhou R; Zhang Z; Deng Z; Chen Z; Tao Z
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Feb; 15(2):59-61. PubMed ID: 12541863
[TBL] [Abstract][Full Text] [Related]
29. [Expression and significance of EBV LMP2A in nasopharyngeal cancer specimens].
Xu J; Yao K; Yu C; Chen X; Li B; Sun H; Zhou F
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(11):484-7. PubMed ID: 16124641
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in host immune response associated genes and risk of nasopharyngeal carcinoma development in Portugal.
Sousa H; Mesquita L; Ribeiro J; Catarino R; Breda E; Medeiros R
Immunobiology; 2016 Feb; 221(2):145-52. PubMed ID: 26391153
[TBL] [Abstract][Full Text] [Related]
31. Presence of in vivo-activated T-cells expressing HLA-DR molecules and IL-2 receptors in peripheral blood of patients with nasopharyngeal carcinoma.
Lakhdar M; Ellouz R; Kammoun H; Ben H'Tira S; Khedhiri N; Kastally R; Fridman WH
Int J Cancer; 1987 Jun; 39(6):663-9. PubMed ID: 3034803
[TBL] [Abstract][Full Text] [Related]
32. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups.
Neel HB; Pearson GR; Taylor WF
Ann Otol Rhinol Laryngol; 1984; 93(5 Pt 1):477-82. PubMed ID: 6093669
[TBL] [Abstract][Full Text] [Related]
33. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma.
Liu MY; Huang YT; Sheen TS; Chen JY; Tsai CH
J Med Virol; 2004 Aug; 73(4):574-82. PubMed ID: 15221902
[TBL] [Abstract][Full Text] [Related]
34. B-cell antigen marker expression in nasopharyngeal carcinoma.
Zhong XY; Senba M; Gu JN; Itakura H
Zentralbl Pathol; 1993 Nov; 139(4-5):281-6. PubMed ID: 7510513
[TBL] [Abstract][Full Text] [Related]
35. Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma.
Galili U; Klein E; Klein G; Singh Bal I
Int J Cancer; 1980 Jan; 25(1):85-9. PubMed ID: 6249765
[TBL] [Abstract][Full Text] [Related]
36. Classification of lymphocytes in nasopharyngeal carcinoma (NPC) biopsies.
Jondal M; Klein G
Biomedicine; 1975 Jun; 23(5):163-5. PubMed ID: 1081410
[TBL] [Abstract][Full Text] [Related]
37. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
38. Humoral and cellular immunity to EBV and lymphoid cell line antigens in human lymphoma.
Levine PH; Connelly RR; Herberman RB; McCoy JL; Fabrizio PL
IARC Sci Publ (1971); 1975; (11 Pt 2):225-35. PubMed ID: 191366
[TBL] [Abstract][Full Text] [Related]
39. [Influence of HPD on immunological functions in patients with nasopharyngeal carcinoma treated by radiotherapy].
Xia Y; Zhang E; Hu Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(3):168-70. PubMed ID: 9639718
[TBL] [Abstract][Full Text] [Related]
40. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
